Amgen, Sandoz, Samsung, and Mylan Launch Biosimilars in Europe (UPDATED)

Published date05 November 2018
Law FirmGoodwin
Subject MatterEU,Prescription Drugs,Biosimilars,Amgen,Mylan Pharmaceuticals,Sandoz,AbbVie,Pharmaceutical Industry,Marketing Authorization Application

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT